SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Lux Encore Sponsor, LP
(Last) (First) (Middle)
C/O LUX HEALTH TECH ACQUISITION CORP.
920 BROADWAY, 11TH FLOOR
(Street)
NEW YORK NY 10010
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Lux Health Tech Acquisition Corp. [ LUXA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/29/2020
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrants $11.5 10/29/2020 P 5,933,333 (1) (1) Class A Common Stock 5,933,333 $1.5 5,933,333 I See footnote(2)
1. Name and Address of Reporting Person*
Lux Encore Sponsor, LP
(Last) (First) (Middle)
C/O LUX HEALTH TECH ACQUISITION CORP.
920 BROADWAY, 11TH FLOOR
(Street)
NEW YORK NY 10010
(City) (State) (Zip)
1. Name and Address of Reporting Person*
Lux Encore Holdings, LLC
(Last) (First) (Middle)
C/O LUX HEALTH ACQUISITION CORP.
920 BROADWAY, 11TH FLOOR
(Street)
NEW YORK NY 10010
(City) (State) (Zip)
1. Name and Address of Reporting Person*
Wolfe Josh
(Last) (First) (Middle)
C/O LUX HEALTH ACQUISITION CORP.
920 BROADWAY, 11TH FLOOR
(Street)
NEW YORK NY 10010
(City) (State) (Zip)
1. Name and Address of Reporting Person*
Hebert Peter
(Last) (First) (Middle)
C/O LUX HEALTH ACQUISITION CORP.
920 BROADWAY, 11TH FLOOR
(Street)
NEW YORK NY 10010
(City) (State) (Zip)
Explanation of Responses:
1. The warrants will become exercisable commencing on the later of 12 months from the closing of the Issuer's initial public offering or 30 days after the completion of the Issuer's initial business combination, and will expire five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation.
2. Lux Encore Sponsor, LP ("Sponsor") is the record holder of the warrants reported herein. Lux Encore Holdings, LLC ("Lux GP") is the general partner of Sponsor. Josh Wolfe and Peter Hebert are the managing members of Lux GP. As such, Lux GP and each of Messers. Wolfe and Hebert may be deemed to share beneficial ownership of the warrants held directly by Sponsor. Lux GP and Messers. Wolfe and Hebert disclaim any beneficial ownership of such shares other than to the extent of their pecuniary interest therein, if any.
Remarks:
Lux Encore Sponsor, LP, By: Lux Encore Holdings, LLC, its general partner, By: /s/ Segolene Scarborough, Attorney-in-Fact for Peter Hebert, Managing Member and Josh Wolfe, Managing Member 11/02/2020
Lux Encore Holdings, LLC, By: /s/ Segolene Scarborough, Attorney-in-Fact for Peter Hebert, Managing Member and Josh Wolfe, Managing Member 11/02/2020
/s/ Segolene Scarborough, Attorney-in-Fact for Josh Wolfe 11/02/2020
/s/ Segolene Scarborough, Attorney-in-Fact for Peter Hebert 11/02/2020
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.